思路迪医药首款RDC药物3D1015IIT研究已完成首例患者给药

医药魔方Info
Oct 24

近期,随着诺华的放射性配体疗法(RDC)药物Pluvicto在转移性去势抵抗性前列腺癌(mCRPC)治疗领域成功获批,2024年其全球销售额已达13.92亿美元,同比增长42%,根据诺华在2025JPM大会上预测,其销售峰值预计超50亿美元。随着诺华核药商业化的成功,核药赛道已成为MNC战略布局的新焦点。2024年至2025年初,礼来、BMS、阿斯利康等巨头通过高溢价收购和战略合作加速布局。据预测...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10